Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan

Leukemia

Volumn 14, Issue 1, 2000, Pages 136-141

  Kelner, M J ^a,d   McMorris, T C ^b   Estes, L ^a   Samson, K M ^a   Trani, N A ^a   MacDonald, J R ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GUILFORD PHARMACEUTICALS INC   (United States)

^d Sea World San Diego   (United States)

Author keywords

HMAF; MGI 114; Synergy; Topotecan; Xenograft

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; ANTILEUKEMIC AGENT; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL STRAIN HL 60; CLINICAL TRIAL; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; MAXIMUM PERMISSIBLE DOSE; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; STEM CELL; TUMOR XENOGRAFT;

EID: 0033959278     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401611     Document Type: Article

References (35)

1. Anchel M, Hervey A, Robbins WJ. Antibiotic substances from Basidiomycetes. VII. Clitocybe illudens. Proc Natl Acad Sci USA 1950; 36: 30-36.
2. McMorris TC, Anchel M. The structures of the Basidiomycete metabolites Illudin S and Illudin M. J Amer Chem Soc 1963; 85: 831-832.
3. McMorris TC, Anchel M. Fungal metabolites. The structure of the novel sesquiterpenoids Illudin-S and -M. J Amer Chem Soc 1965; 87: 1594-1600.
4. Kelner MJ, McMorris TC, Beck WT, Zamora IM, Taetle R. Preclinical evaluation of illudins as anticancer agents. Cancer Res 1987; 47: 3186-3189.
5. Kelner MJ, McMorris TC, Taetle R. Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity. J Natl Cancer Inst 1990; 82: 1562-1565.
6. Kelner MJ, McMorris TC, Estes L, Rutherford M, Montoya M, Goldstein J, Samson K, Starr R, Taetle R. Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells. Unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents. Biochem Pharmacol 1994; 48: 403-409.
7. Kelner MJ, McMorris TC, Taetle R. In vitro and in vivo studies on the anticancer activity of dehydroilludin M. Anticancer Res 1995; 15: 873-878.
8. Kelner MJ, McMorris TC, Estes L, Starr RJ, Rutherford M, Montoya M, Samson KM, Taetle R. Efficacy of Acyltulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells. Cancer Res 1995; 55: 4936-4940.
9. Kelner MJ, McMorris TC, Estes L, Wang W, Samson KM, Taetle R. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Invest New Drugs 1996; 14: 161-167.
10. MacDonald JR, Muscoplat CC, Dexter DL, Mangold GL, Chen SF, Kelner MJ, McMorris TC, Von Hoff DD. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res 1997; 57: 279-283.
11. Kelner MJ, McMorris TC, Estes L, Samson KM, Bagnell RD, Taetle R. Efficacy of MGI 114 against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft. Eur J Cancer 1998; 34: 908-913.
12. Barrera H, MacDonald JR, Hilsenbeck S, Weitman S. In vitro antitumor activity of MGI 114 in combination with topotecan, cisplatin, etoposide, or gemcitabine. Proc Amer Assoc Cancer Res 1998; 39: 527.
13. Mangold G, MacDonald J, Von Hoff D, Weitman S. Antitumor activity of MGI 114 against two human prostate tumor xenografts. 10th NCI-EORTC Symposium Proceedings, 1998, p 37.
14. Marty J, MacDonald J, Mangold G, Weitman S, Von Hoff D. Evidence of synergistic antitumor activity with MGI 114 in combination with Irinotecan or 5-fluorouracil against a human colon tumor xenograft model. Proc Amer Assoc Cancer Res 1998; 39: 527.
15. Bogden AE, Cobb WR, Breitman TR, Wolpert-DeFilippes MK, DeLarco B, Vendetti JM, Plowman J, Shoemaker RH. HL60/ascites tumor: a transplantable human tumor model for in vivo testing of differentiation inducers. Proc Amer Assoc Cancer Res 1985; 26: 34.
16. Omasum M, Asemia J, Breitman TR. Retinoid acid-induced monocytic differentiation of HL60/MRI, a cell lined derived from a transplantable HL60 tumor. Cancer Res 1987; 47: 1434-1440.
17. Omasum M, Breitman TR. Changes in c-myc, c-f's, and N-ras proto-oncogene expression associated with retinoid acid-induced monocytic differentiation of human leukemia HL60/MRI cells. Cancer Res 1988; 48: 6733-6738.
18. Chou T-C, Talky P. Applications of median-effects principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. In: Harrap KR, Connors TA (eds). New Avenues in Developmental Cancer Chemotherapy. Academic Press: New York, 1987, pp 37-64.
19. Chou T-C. The median-effect principle and the combination index for quantification of synergism and antagonism. In: Chou T-C, Rideout DE (eds). Synergism and Antagonism in Chemotherapy. Academic Press: New York, 1991, pp 61-102.
20. Crocke ST, Bradner WT. Mitomycin C: a review. Cancer Treat Rev 1976; 3: 121-139.
21. Weinreb S, McMorris TC, Anchel M. Fulvenes derived from Illudin S. Tetrahedron Lett 1971; 38: 3489-3491.
22. McMorris TC, Kelner MJ, Wang W, Diaz MA, Estes LA, Taetle R. Acylfulvenes, a new class of potent antitumor agents. Experientia 1996; 52: 75-80.
23. McMorris TC, Kelner MJ, Wang W, Yu J, Estes LA, Taetle R. (Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties. J Nat Prod 1996; 59: 896-899.
24. Taetle R, Rosen F, Abramson I, Bendetti J, Howell S. Use of nude mouse xenografts as preclinical drug screen: in vivo activity of established chemotherapeutic agents against melanomas and ovarian carcinoma xenografts. Cancer Treat Rep 1987; 71: 297-304.
25. Altman DG. Practical Statistics in Medical Research. Chapman and Hall: New York, 1991, pp 355-394.
26. Webb JL. Effects of more than one inhibitor. In: Webb JL (ed). Enzymes and Metabolic Inhibitors, vol 1. Academic Press: New York, 1963, pp 66-79.
27. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47: 331-385.
28. Chou T-C, Motzer JR, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of Taxol, Topotecan, and Cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-1523.
29. Kaufman SH, Peerebom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK. Cytotoxic effects of Topotecan combined with various anticancer agents in human cell lines. J Natl Cancer Inst 1996; 88: 734-741.
30. Woynarowski JM, Napier C, Koester SK, Chen S-F, Troyer D, Chapman W, MacDonald JR. Effect on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene, 6-hydroxymethylacylfulvene (HMAF, MGI 114). Biochem Pharmacol 1997; 54: 1181-1193.
31. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F. In vitro and in vivo interactions between cisplatin and topotecan. Cancer Chemother Pharmacol 1998; 41: 185-390.
32. Duget M. When helicase and topoisomerase meet! J Cell Sci 1997; 110: 1345-1350.
33. Burris H, Kuhn J, Johnson K, Von Hoff D. SKF 104864 (Topotecan): preclinical studies of a new topoisomerase inhibitor. Proc Am Soc Clin Oncol 1990; 11: 216.
34. Rowinsky E, Grochow L, Hendritks C. Phase I and pharmacologic study of topotecan (SKF 104864): a novel topoisomerase I inhibitor. Proc Am Soc Clin Oncol 1991; 10: 93.
35. Senser NN, Rakvica R, Chao H, Smith S. A phase II trial of MGI 114 in patients with hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 1999; 18: 321A.